Arvinas logo
Close this search box.

KRAS-Targeted PROTAC® Degraders are Broadly Efficacious Against KRAS Dependent Tumor Models

Katie Smith

March 8, 2023
Targeting RAS Conference (AACR Special Conference)


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content